Nifty  22570.35  167.95  (0.75%)

Sensex  74339.44  486.50  (0.66%)

USDINR  83.33  0.01  (0.02%)

Lupin launches Silodosin Capsules
(04 Dec 2018)
Lupin announced the launch of Silodosin Capsules 4mg and 8mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Silodosin Capsules 4mg and 8mg; is the generic equivalent of AIIergan's Rapaflo®. An alpha-l adrenergic receptor antagonist, it is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Rapaflo® had annual sales of $198.5 million in the US (IQVIA MAT September 2018).